Comparison between Canara Robeco IPO and Corona Remedies IPO.
Canara Robeco IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Corona Remedies IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Canara Robeco IPO is up to ₹1,326.13 Cr whereas the issue size of the Corona Remedies IPO is up to ₹655.37 Cr. The final issue price of Canara Robeco IPO is ₹266.00 per share and of Corona Remedies IPO is ₹1,062.00 per share.
| Canara Robeco IPO | Corona Remedies IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹253.00 per share | ₹1,008.00 per share |
| Issue Price (Upper) | ₹266.00 per share | ₹1,062.00 per share |
| Issue Price (Final) | ₹266.00 per share | ₹1,062.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ₹54.00 per share | |
| Market Lot Size | 56 shares | 14 shares |
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 4,98,54,357 shares | 61,74,051 shares |
| OFS Issue Size (Amount) | up to ₹1,326.13 Cr | up to ₹655.37 Cr |
| Issue Size Total | 4,98,54,357 shares | 61,74,051 shares |
| Issue Size Total (Amount) | up to ₹1,326.13 Cr | up to ₹655.37 Cr |
Canara Robeco IPO opens on Oct 09, 2025, while Corona Remedies IPO opens on Dec 08, 2025. The closing date of Canara Robeco IPO and Corona Remedies IPO is Oct 13, 2025, and Dec 10, 2025, respectively.
| Canara Robeco IPO | Corona Remedies IPO | |
|---|---|---|
| Anchor Bid Date | Oct 08, 2025 | Dec 05, 2025 |
| Issue Open | Oct 09, 2025 | Dec 08, 2025 |
| Issue Close | Oct 13, 2025 | Dec 10, 2025 |
| Basis Of Allotment (Tentative) | Oct 14, 2025 | Dec 11, 2025 |
| Initiation of Refunds (Tentative) | Oct 15, 2025 | Dec 12, 2025 |
| Credit of Share (Tentative) | Oct 15, 2025 | Dec 12, 2025 |
| Listing date (Tentative) | Oct 16, 2025 | Dec 15, 2025 |
| Anchor Lockin End date 1 | Nov 12, 2025 | Jan 09, 2026 |
| Anchor Lockin End date 2 | Jan 11, 2026 | Mar 10, 2026 |
Canara Robeco IPO P/E ratio is 27.82, as compared to Corona Remedies IPO P/E ratio of 43.47.
| Canara Robeco IPO | Corona Remedies IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Canara Robeco Asset Management Co.Ltd.'s revenue increased by 27% and profit after tax (PAT) rose by 26% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)Corona Remedies Ltd.'s revenue increased by 18% and profit after tax (PAT) rose by 65% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100 | 72.5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 75 | 69 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 27.82 | 43.47 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹5304.50 Cr. | ₹6495.20 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 27.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 41.32% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹9.56 | ₹24.43 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 36.17% | 24.65% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Canara Robeco IPO Retail Individual Investors (RII) are offered 1,74,49,025 shares while in Corona Remedies IPO retail investors are offered 1,74,49,025 shares. Qualified Institutional Buyers (QIB) are offered 99,70,872 shares in Canara Robeco IPO and 12,23,203 shares in Corona Remedies IPO.
| Canara Robeco IPO | Corona Remedies IPO | |
|---|---|---|
| Anchor Investor Reservation | 1,49,56,306 shares | 18,34,804 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 99,70,872 shares | 12,23,203 shares |
| NII | 74,78,154 shares | 9,17,403 shares |
| RII | 1,74,49,025 shares | 21,40,606 shares |
| Employee | 0 shares | 58,035 shares |
| Others | ||
| Total | 4,98,54,357 shares | 61,74,051 shares |
Canara Robeco IPO subscribed 9.74x in total, whereas Corona Remedies IPO subscribed 144.54x.
| Canara Robeco IPO | Corona Remedies IPO | |
|---|---|---|
| QIB (times) | 25.92x | 293.80x |
| NII (times) | 6.45x | 220.18x |
| Big NII (times) | 6.77x | 246.67x |
| Small NII (times) | 5.82x | 167.20x |
| RII (times) | 1.91x | 30.39x |
| Employee (times) | 15.56x | |
| Other (times) | ||
| Total (times) | 9.74x | 144.54x |
